Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...

Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...

Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the ...

Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...

"Those with the highest burden of comorbidity had over a 30% increased risk of having disability worsening," Salter said. "In ...

Bucks County resident Joseph “Smiley” Terinoni was recently presented with a citation from the Pennsylvania House of ...

A pioneering study presented today at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple sclerosis (MS).

Novartis AG (NYSE:NVS) released new data Wednesday from the ALITHIOS open-label extension study. Data show first-line ...

High-dose cholecalciferol (vitamin D) is safe and can nearly double the time it takes for clinically isolated syndrome to ...

This summary highlights major health news, including EU's endorsement of Novo Nordisk's Wegovy for heart conditions in ...

A short course of Mavenclad can provide long-term reductions in disease activity and disability progression in highly active ...

Available disease-modifying therapies can prevent relapses and relapse-associated worsening in people with multiple sclerosis by targeting autoimmunity through various mechanisms. However, these ...